logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.
  • Otsuka America Pharmaceutical, Inc. drugs

    FiltersReset Filters
    7 results
    • abilify

      (ARIPIPRAZOLE)
      Otsuka America Pharmaceutical, Inc.
      Usage: ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia, acute manic and mixed episodes associated with Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette's disorder.
    • abilify maintena

      (aripiprazole)
      Otsuka America Pharmaceutical, Inc.
      Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.
    • abilify mycite

      (ARIPIPRAZOLE)
      Otsuka America Pharmaceutical, Inc.
      Usage: ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (including both acute and maintenance phases), and as adjunctive therapy for Major Depressive Disorder. It features an Ingestible Event Marker (IEM) sensor to track medication ingestion.
    • busulfex

      (busulfan)
      Otsuka America Pharmaceutical, Inc.
      Usage: BUSULFEX is indicated for use alongside cyclophosphamide as a conditioning regimen before allogeneic hematopoietic progenitor cell transplantation in patients with chronic myelogenous leukemia.
    • jynarque

      (tolvaptan)
      Otsuka America Pharmaceutical, Inc.
      Usage: JYNARQUE is indicated to slow the decline of kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
    • rexulti

      (brexpiprazole)
      Otsuka America Pharmaceutical, Inc.
      Usage: REXULTI is indicated as an adjunctive treatment for major depressive disorder in adults, for the treatment of schizophrenia in adults and patients aged 13 and older, and for agitation associated with Alzheimer's disease. It is not intended for as-needed treatment of agitation.
    • samsca

      (tolvaptan)
      Otsuka America Pharmaceutical, Inc.
      Usage: SAMSCA® is indicated for treating clinically significant hypervolemic and euvolemic hyponatremia in patients, including those with heart failure and SIADH. It is not recommended for urgent serum sodium increases to prevent neurological symptoms, and its symptomatic benefits have not been established.